Capillary Blood Glucose Measurements Research Articles

Comparison of Glucose Measurement Techniques Using Venous and Capillary Blood Samples in Diabetics Regarding Patient Satisfaction

Aim: This study was conducted to compare the satisfaction of patients diagnosed with diabetes mellitus regarding blood glucose measurement based on the blood glucose measurement techniques (intravenous and capillary) used. Material and Method: A randomized controlled study was conducted with 110 patients with diabetes mellitus. Patients were randomized into the experimental group (n=55) and control group (n=55). Patient Information Form, Diabetes Fear of Injecting and Self-testing Questionnaire (D-FISQ), and Blood Glucose Measurement Patient Satisfaction Form were used in the study. The control group patients had their blood sugar measured using capillary blood from a finger prick. The experimental group patients had their blood glucose measured intravenously using venous blood, followed by capillary blood glucose measurement from a finger prick. Data analysis was conducted using chi-square test and independent t-test. Results: There were statistically significant differences in the satisfaction of diabetic patients with the blood glucose measurement technique between the use of venous blood and intravenous blood glucose measurement by finger prick (p

A veterinary-calibrated point-of-care glucometer accurately measures blood glucose concentration in dogs and cats.

To determine the clinical and analytical accuracy of a new veterinary-calibrated portable blood glucose monitor (PBGM) compared to a reference laboratory analyzer. Client-owned dogs (n = 77) and cats (n = 64). Peripheral and paired capillary whole-blood glucose concentrations measured via PBGM were compared to plasma glucose concentrations measured via a Cobas c501 reference analyzer (Roche). Analytical accuracy was evaluated with the Spearman rank correlation coefficient, Bland-Altman difference plot analysis, and Deming regression. Clinical accuracy was evaluated with Parkes error grid analysis. Paired peripheral and capillary blood samples were compared with the Wilcoxon matched-pairs signed-rank test. There was a high correlation between PBGM and reference analyzer readings in dogs and cats. Human quality assurance standards (International Organization for Standardization 15197:2013 guidelines) for analytical accuracy were met for 95% of feline peripheral blood samples and 89% of canine samples. Similar veterinary standards (American Society of Veterinary Clinical Pathology guidelines) were met for 89% of canine and 92% of feline peripheral blood glucose measurements. Error grid analysis showed that all peripheral canine and 97% of feline measurements were clinically accurate (zone A). Any altered clinical decision for the remaining feline measurements was expected to minimally impact outcome (zone B). No significant difference was found between peripheral and capillary blood glucose measurements in either species. The PBGM produced clinically accurate results and is suitable for use in veterinary and home settings to measure blood glucose.

Performance of a Novel Continuous Glucose Monitoring Device in People With Diabetes.

In this multicenter study, performance of a novel continuous glucose monitoring (CGM) system was evaluated. Adult participants with diabetes were included in the study. They each wore three sensors of the CGM system on the upper arms for up to 14 days. During four in-clinic visits, frequent comparison measurements with capillary blood glucose (BG) samples were performed. The primary endpoint was the 20/20 agreement rate (AR): the percentage of CGM readings within ±20 mg/dL (at BG values <100 mg/dL) or ±20% (at BG values ≥100 mg/dL) of the comparator. Further evaluations included mean absolute relative difference (MARD) and 20/20 AR in different BG ranges and across the wear time. Data from 48 participants and 139 sensors were analyzed. During in-clinic sessions the 20/20 AR was 90.5% and the MARD was 9.2%. For BG ranges <70, 70-180, and >180 mg/dL, 20/20 AR was 94.3%, 89.0%, and 92.5%, respectively. At the beginning, middle, and end of sensor wear time, 20/20 AR was 92.8%, 91.5%, and 85.9%, respectively. The 14-day survival probability was 82.4%. Pain and bleeding after sensor insertion were within the expected range. Based on the study outcome, the use of the device is regarded as safe. The system showed a good performance compared to capillary BG measurements. This level of accuracy could be shown over the entire measurement range, especially in the low glycemic range, and the whole wear time of the sensors. The results of this study are supporting a non-adjunctive use of the device.

How to Use Continuous Glucose Monitoring Efficiently in Diabetes Management: Opinions and Recommendations by German Experts on the Status and Open Questions.

Today, continuous glucose monitoring (CGM) is a standard diagnostic option for patients with diabetes, at least for those with type 1 diabetes and those with type 2 diabetes on insulin therapy, according to international guidelines. The switch from spot capillary blood glucose measurement to CGM was driven by the extensive and immediate support and facilitation of diabetes management CGM offers. In patients not using insulin, the benefits of CGM are not so well studied/obvious. In such patients, factors like well-being and biofeedback are driving CGM uptake and outcome. Apps can combine CGM data with data about physical activity and meal consumption for therapy adjustments. Personalized data management and coaching is also more feasible with CGM data. The same holds true for digitalization and telemedicine intervention ("virtual diabetes clinic"). Combining CGM data with Smart Pens ("patient decision support") helps to avoid missing insulin boluses or insulin miscalculation. Continuous glucose monitoring is a major pillar of all automated insulin delivery systems, which helps substantially to avoid acute complications and achieve more time in the glycemic target range. These options were discussed by a group of German experts to identify concrete gaps in the care structure, with a view to the necessary structural adjustments of the health care system.

Cardiovascular Risk Profile on the Island of Santiago-Cabo Verde (PrevCardio.CV Study).

Cerebrocardiovascular diseases are a major global public health concern, significantly impacting morbidity, mortality, and posing substantial socio-economic challenges. In Cabo Verde, non-communicable diseases have become the leading causes of morbidity and mortality. This study aimed to estimate the prevalence of risk factors for cerebrocardiovascular diseases and their association with cardiac electrical alterations in adults on Santiago Island, Cabo Verde. A cross-sectional population-based study using simple random sampling was conducted on individuals over 18 years of age. The sample size of 599 was based on Santiago Island's 2021 population projection. Data collection occurred in October and November 2021, involving questionnaires on risk factors and cerebrocardiovascular diseases; blood pressure assessments; and capillary blood glucose measurements. The sample was predominantly female, with the 18-27 age group being the largest. Key risk factors included physical inactivity (65.1%), BMI ≥ 25 kg/m2 (42.6%), hypertension (32.6%), and family history of cerebrocardiovascular diseases (19.9%). Other factors were alcoholism (14.4%), hypercholesterolemia (8.3%), smoking (7.3%), diabetes (4.5%), and hypertriglyceridemia (1.3%). Notably, 9.3% had no risk factors, 27.5% had one, 36.2% had two, and 26.9% had three or more. There is a high prevalence of risk factors for cerebrocardiovascular diseases on Santiago Island, particularly among females.

Accuracy of a continuous glucose monitoring system applied before, during, and after an intense leg-squat session with low- and high-carbohydrate availability in young adults without diabetes

PurposeThe aim was to assess the accuracy of a continuous blood glucose monitoring (CGM) device (Abbott FreeStyle Libre 3) against capillary blood glucose measurement (BGM) before, during, and after an intense lower body strength training session in connection with high- versus low-carbohydrate breakfasts.MethodsNine adults (22 ± 2 years) completed a strength training session (10 × 10 at 60% 1RM) twice after high-carbohydrate and twice after low-carbohydrate breakfasts. CGM accuracy versus BGM was assessed across four phases: post-breakfast, pre-exercise, exercise, and post-exercise.ResultsOverall fed state mean BGM levels were 84.4 ± 20.6 mg/dL. Group-level Bland–Altman analysis showed acceptable agreement between CGM and BGM across all phases, with mean biases between − 7.95 and − 17.83 mg/dL; the largest discrepancy was in the post-exercise phase. Mean absolute relative difference was significantly higher post-exercise compared to pre-exercise and exercise phases, for overall data and after the high-carbohydrate breakfast (all p ≤ 0.02). Clark Error Grid analysis showed 50.5–64.3% in Zone A and 31.7–44.6% in Zone B, with an increase in treatment errors during and after exercise.ConclusionIn this group of healthy participants undergoing strength training, CGM showed satisfactory accuracy in glucose monitoring but varied substantially between individuals compared to BGM and fails in meeting clinical criteria for diabetic monitoring. CGM could aid non-diabetic athletes by tracking glucose fluctuations due to diet and exercise. Although utilization of CGM shows potential in gathering, analyzing, and interpreting interstitial glucose for improving performance, the application in sports nutrition is not yet validated, and challenges in data interpretation could limit its adoption.

Prevalence and Risk Factors of Spontaneous Hypoglycemia in Hospitalized Patients: Cross-Sectional Observational Study and Literature Review

Introduction: Spontaneous hypoglycemia is a blood glucose level below 70 mg/dL unrelated to insulin or oral hypoglycemic agents. Objectives: To assess the prevalence of spontaneous hypoglycemia (&lt;70 mg/dL) in adult patients admitted to Hospital Santa Izabel in 2023. Additionally, a narrative review was conducted to evaluate the prevalence, risk factors, main contributing factors, and mortality associated with spontaneous hypoglycemia in hospitalized patients. Methods: A cross-sectional observational study reviewed an electronic medical record database of adult patients. Capillary blood glucose measurements from patients admitted to general wards, intensive care units (ICUs), and emergency services at Hospital Santa Izabel (HSI) in 2023 were analyzed. A narrative review was also performed through a non-systematic PubMed search using the terms hypoglycemia, mortality, hospital, and individuals without diabetes. The search yielded 61 articles, which, along with reference analysis, brought the total to 81 articles. After excluding duplicates and studies irrelevant to the topic, 10 articles were selected for analysis. Results: In 2023, HSI recorded 6,609 episodes of hypoglycemia, accounting for 2.63% of the blood glucose measurements. The prevalence of spontaneous hypoglycemia in the reviewed articles ranged from 0.01% to 0.51%. Spontaneous hypoglycemia occurs more frequently in ICU patients and the elderly. Common risk factors included heart failure, renal failure, malignancy, and pre-existing diabetes. Severe conditions such as cirrhosis, multiple organ failure, polytrauma, and sepsis were also associated with hypoglycemia. Moreover, spontaneous hypoglycemia was linked to higher mortality, with 5 out of 10 studies showing mortality rates 2 to 3 times higher in patients who experienced at least one episode. This association was not commonly observed in insulin-induced hypoglycemia. Conclusion: Spontaneous hypoglycemia in hospitalized patients is a rare event, typically associated with severe acute conditions and advanced age. It is more frequently linked to higher mortality compared to medication-induced hypoglycemia, with mortality rates correlating with the severity of the hypoglycemic episodes.

Can prophylactic oral dextrose solution prevent hypoglycemia in high risk newborns?

Prophylactic oral dextrose gel recommended to prevent hypoglycaemia in high risk babies is not readily available and affordable. This study was therefore conducted to find out if oral dextrose solution decreases the incidence of hypoglycaemia in high risk neonates. This study included 186 high risk newborns. Oral 10% dextrose 2ml/kg was given at 30 minutes, 2, 6 and 12 hours of life, along with direct breastfeeding. Capillary blood glucose measurement was monitored at 2, 6, 12, 24, 48 and 72 hours of life. Low blood sugar levels were confirmed by simultaneous venous blood sampling. Statistical tests used were chi square for proportions and ANOVA for means. Of the 186 high risk babies maximum babies were small for gestational age (n = 68, 36.5%). Among the high risk babies, 7 (3.7%) developed hypoglycaemia. All were asymptomatic. A higher proportion of hypoglycaemia was seen IUGR babies (n = 2/9, 22.2%) and in those delivered by caesarean section (n =3/71, 4.2%). Compared to the incidence of hypoglycaemia (7.2%) in the historical control group the incidence of hypoglycaemia (3.7%) in interventional group was lower though statistically not significant (p=NS). There is a decrease in the incidence of hypoglycemia in high-risk infants given prophylactic oral dextrose solution. However, this trend was not statistically significant.

Glycaemic outcomes in hospital with IDegAsp versus BIAsp30 premixed insulins.

IDegAsp (Ryzodeg70/30), a unique premixed formulation of long-acting insulin degludec and rapid-acting insulin aspart, is increasing in use. Management of IDegAsp during hospitalisation is challenging because of degludec's ultra-long duration of action. We investigated inpatient glycaemia in patients treated with IDegAsp compared to biphasic insulin aspart (BIAsp30; Novomix30). We performed a retrospective observational study at two hospitals assessing inpatients with type 2 diabetes treated with IDegAsp or BIAsp30 prior to and during hospital admission. Standard inpatient glycaemic outcomes were analysed based on capillary blood glucose (BG) measurements. We assessed 88 individuals treated with IDegAsp and 88 HbA1c-matched individuals treated with BIAsp30. Patient characteristics, including insulin dose at admission, were well matched, but the IDegAsp group had less frequent twice-daily insulin dosing than the BIAsp30 group (49% vs 87%, P < 0.001). Patient-days with BG <4 mmol/L were not different (10.6% vs 9.9%, P = 0.7); however, the IDegAsp group had a higher patient-day mean BG (10.4 (SD 3.4) vs 10.0 (3.4) mmol/L, P < 0.001), and more patient-days with mean BG >10 mmol/L (48% vs 38%, P < 0.001) compared to the BIAsp30 group. Glucose was higher in the IDegAsp group in the evening (4 PM to midnight) (11.6 (SD 4.0) vs 10.9 (4.6) mmol/L, P = 0.004), but not different at other times during the day. Inpatients treated with IDegAsp compared to BIAsp30 had similar hypoglycaemia incidence, but higher hyperglycaemia incidence, potentially related to less frequent twice-daily dosing. With the increasing use of IDegAsp in the community, development of hospital management guidelines for this insulin formulation is needed.

Quantifying the effect of glucose 6-phosphate dehydrogenase deficiency on glycated hemoglobin values in children and adolescents with type 1 diabetes

The primary objectives of the study were (a) to confirm that glucose 6-phosphate dehydrogenase (G6PD) deficiency affects HbA1c values in a sample of children and adolescents with type 1 diabetes (T1D) and (b) to quantify this effect so that a correction can be applied to the HbA1c values found in current clinical practice. The following data were collected: age, sex, G6PD, number of daily capillary blood glucose measurements, 90-day average blood glucose levels prior to the study, HbA1c, and glycated hemoglobin estimated (eA1c) obtained from blood glucose levels. Patients were divided into three groups based on G6PD values: deficient, intermediate, and nondeficient. In each group, a comparison between the average eA1C and HbA1c values was performed. Then, the difference between the eA1c and HbA1c values of each patient and the mean of the differences (MD) of all patients was calculated within the three groups. Finally, a comparison of the MD values between groups was performed. Seventy-four subjects with T1D were studied. Based on the G6PD value, 33 subjects were deficient, 8 were intermediate, and 33 subjects were nondeficient. In deficient patients, the eA1c values were significantly higher than the HbA1c values. In the other two groups, however, there were no differences. The MD values between the three groups were significantly different. In deficient patients, MD values were higher than those in intermediate and in nondeficient patients. No difference was found between intermediate and nondeficient subjects. Our study confirms that G6PD deficiency affects HbA1c values in children and adolescents with T1D, both in deficient subjects and, to a much lesser extent, in intermediate subjects. In deficient subjects, there is an average reduction in HbA1c attributable to enzyme deficiency of 1.3% (14 mmol/mol) and in intermediate subjects of 0.3% (3 mmol/mol).

Clinical utility of point-of-care glucose testing in the assessment of gestational diabetes: Prospective cohort study.

To assess the clinical utility of point-of-care (POC) capillary blood glucose (CBG) testing in the assessment of gestational diabetes mellitus (GDM) during oral glucose tolerance test (OGTT). Prospective cohort study. Antenatal clinics at King's College Hospital. Women screened for GDM between March and June 2020. The CBG was measured using the POC StatStrip® test and the venous plasma glucose (VPG) was measured by Roche analyser (Cobas 8000 c702). GDM was diagnosed based on the 2015 National Institute for Health and Clinical Excellence (NICE) Clinical Guideline criteria. The two methods were compared statistically using Analyse-It 5.40.2. Diagnostic sensitivity, specificity, positive and negative predictive values (PPV and NPV) for the POC StatStrip® test, compared with VPG measured by reference laboratory method. A total of 230 women were included. The number and percentage of women with glucose concentrations above the GDM threshold using the POC StatStrip® test versus laboratory VPG measurement was 15 (6.5%) versus eight (3.4%) at fasting and 105 (45.6%) versus 72 (31.1%) at 2 h, respectively. The sensitivity and specificity values (and 95% CIs) for the POC StatStrip® test were 88% (52%-99%) and 97% (93%-98%) at fasting and 97% (91%-99%) and 79% (71%-84%) at 2 h, respectively. However, the specificity and the NPV for the POC StatStrip® test for concentrations of ≤5.0 mmol/L at fasting or <7.5 mmol/L at 2 h were 100%, and the sensitivity and the PPV for concentrations of >9.5 mmol/L at 2 h were 100%. In our cohort the POC measurement of CBG cannot entirely replace the laboratory method for the OGTT; however, it can be used to rule out/rule in GDM for glucose concentrations of ≤5.0 mmol/L at fasting or <7.5/>9.5 mmol/L at 2 h.

Hyperglycemia in hospital: an independent marker of infection, acute kidney injury & stroke for hospital inpatients.

Hyperglycemia in hospital inpatients without pre-existing diabetes is associated with increased mortality. However, the independent contribution of hyperglycemia to healthcare-associated infection (HAI), acute kidney injury (AKI), and stroke is unclear. To investigate the relationship between hyperglycemia and adverse clinical outcomes in hospital for patients with and without diabetes. Diabetes IN-hospital: Glucose and Outcomes (DINGO) was a 26-week (October 2019 - March 2020) prospective cohort study. Clinical and glucose data were collected up to the 14th day of admission. Primary stratification was by hyperglycemia, defined as ≥2 random capillary blood glucose (BG) measurements ≥11.1 mmol/L (≥200 mg/dL). Propensity weighting for nine clinical characteristics, was performed to allow interrogation of causality. To maintain the positivity assumption, patients with HbA1c > 12.0% were excluded and pre-hospital treatment not adjusted for. The Royal Melbourne Hospital, a quaternary referral hospital in Melbourne, Australia. Admissions with at least two capillary glucose values and length of stay >24 hours were eligible, with half randomly sampled. HAI, AKI, stroke, and mortality. Of 2,558 included admissions, 1,147 (45%) experienced hyperglycemia in hospital. Following propensity-weighting and adjustment, hyperglycemia in hospital was found to, independently of nine covariables, contribute an increased risk of in-hospital HAI (130 [11.3%] vs.100 [7.1%], adjusted odds ratio [aOR] 1.03, 95% confidence interval [95%CI] 1.01-1.05, p = 0.003), AKI (120 [10.5%] vs. 59 [4.2%], aOR 1.07, 95%CI 1.05-1.09, p < 0.001), and stroke (10 [0.9%] vs. 1 [0.1%], aOR 1.05, 95%CI 1.04-1.06, p < 0.001). In hospital inpatients (HbA1c ≤ 12.0%), irrespective of diabetes status and pre-hospital glycaemia, hyperglycemia increases the risk of in-hospital HAI, AKI, and stroke compared with those not experiencing hyperglycemia.

Reliability and accuracy of bedside capillary blood glucose measurement by glucometers compared to venous blood glucose in critically ill patients: A facility based cross-sectional study

BackgroundThe traditional reference standard, venous blood glucose requires venipuncture and laboratories usually return the test results after 60 minutes. Our aim was to determine the agreement accuracy of glucose (capillary) levels obtained by POC glucometers with glucose (venous) values by standard laboratory method (glucose-oxidase) and to assess whether and to what extent the glucometers perform uniformly well across the entire range of blood glucose values. MethodsWe compared the diagnostic accuracy of two- point of care glucometers with laboratory venous glucose, the reference standard using Bland- Altman plots and Clark error grid method to analyse the results. ResultsThis study included a total of 110 patients (38[34%] women; mean age 52.1 years (SD, 17.3); range 14 to 85 years. Fourteen patients (12%) were known to have diabetes. The mean glucose value (glucometer 1) was 152.9 mg/dL (SD 83.1); range= 48 to 501 mg/dL; that by glucometer 2 was 152.2 mg/dL (SD 76.2); range= 30 to 458 mg/dL and by the laboratory was 148.6 mg/dL (SD 81.5); range= 52 to 480 mg/dL. Of the 110 subjects, 2(2%) had blood glucose below 70 mg/dL; 85(77%) between 70 and 180 mg/ dL and 23(21%) had blood glucose exceeding 180 mg/dL. The Bland- Altman plot showed a bias of 4 mg% (95%CI -9.8 to +1.1); and the limits of agreement were -63 and +54 mg%. The area under the receiver operating characteristic curve for the two glucometers was 0.92 and 0.93 respectively. ConclusionsPoint of care glucose, measured by glucometers was in agreement with the venous glucose estimation. Both glucometers were equally accurate and performed uniformly well across the wide range of blood glucose values.

Be mindful of the blood glucose measurement: The relevance of blood glucose in the eye emergency department

Aims/Purpose: Diabetic eye disease is a leading cause of blindness worldwide and diabetes‐related eye conditions are frequent presentations in Eye Emergency Departments (EEDs). Early detection and intervention of inadequate blood glucose control in the EED could be sight‐saving.The aims of this study are to determine the: prevalence of pre‐existing diabetes mellitus (DM) in the EED. prevalence of suboptimal (HbA1c 53–70 mmol/mol) or poor (HbA1c &gt;70 mmol/mol) glycaemic control in the EED. proportion of diabetes patients with this diagnosis documented in the EED. proportion of EED patients at risk of undiagnosed diabetes. number of EED patients that had a capillary blood glucose measurement (BgM). Methods: A retrospective review of 683 patients attending the EED over 10 consecutive weekdays at Manchester Royal Eye Hospital, Manchester, United Kingdom. The following parameters were assessed: EED documentation: patient age, gender, presentation, diagnosis, management plan and whether a BgM was done. General Practitioner records: diabetes diagnosis cross‐referenced with EED documentation. If diabetes patients: diabetes type, duration, and glycaemic control. Potentially undiagnosed diabetes. Results: The prevalence of diabetes patients was 9.5%–64.6% of these patients had diabetes documented in EED and 1 had a capillary BgM. 70.7% of diabetes patients had pre‐existing suboptimal [33.8%] or poor [36.9%] glycaemic control. 8.5% of patients were considered high‐risk for undiagnosed diabetes of which 1 had a BgM.Conclusions: There is a high prevalence of diabetes patients in the EED, and most have inadequate glycaemic control. This makes the EED an important setting to detect patients at high risk of diabetes‐related ocular disease and complications. BgM testing for all suspected patients is a quick test to allow earlier detection and intervention of inadequately controlled diabetes and reduce the risk of diabetes‐related vision loss.

Comparison of Two Methods for the Measurement of Blood Plasma and Capillary Blood Glucose in Tropical Highland Grassing Dairy Cows.

(1) Background: There is lack of published studies validating specific cow-side glucometers such as Centrivet GK (CVGK). (2) Methods: The aims were (1) to measure and compare the blood glucose concentrations in 52 tropic highland grassing cows by using CVGK and the traditional enzymatic/photometric assay (EPA) in plasma and serum (reference method) and (2) to establish if glucose concentrations obtained via these methods could be affected by several demographic and zootechnical parameters of the dairy herd evaluated. (3) Results: Glucose concentrations were significantly (p = 0.00) affected by the method used for their measurement. The intra-assay coefficient of variation (CV) for glucose concentrations in plasma EPA and for CVGK was 14% for both methods with serum EPA, whereas the inter-assay CV for plasma EPA and CVGK was 8% and 13.7%, respectively, with serum EPA. Pearson correlation coefficient calculations between the reference method in serum and plasma presented a slightly positive significant (p = <0.000) correlation (r = 0.56), whereas there was not a significant (p = 0.413) correlation between serum EPA and CVGK (r = 0.135). The Passing and Bablok regressions were out of the ideal expected values for the slope (β = 1) and the intercept (α = 0) (11), whereas the Bland-Altman plots showed a bias of 5.29 ± 11.73 (mg/dL) for serum and plasma and 11.01 ± 15.74 (mg/dL) for serum and CVGK. The ROC curve showed no sensitivity in detecting normoglycemic cows (area = 53.7 %, e.d = 12.5 %, p = 0.759) for CVGK when compared to plasma EPA (area = 36.1 %, e.d = 14.2 %, p = 0.256). Plasma EPA exhibited a better but not significant effect in detecting hyperglycemic cows (area = 63.9%, e.d = 14.2%, p = 0.256) when compared to HHD (area = 46.3 %, e.d = 12.5 %, p = 0.759). General glucose concentrations, independently of the method used, were significantly (p = <0.001) greater in young cows when compared to adult and old cows. (4) Conclusions: Glucose concentration measurement in plasma by using EPA or in capillary blood via CVGK were not reliable methods when compared with the reference method.

TYPE 2 DIABETES MELLITUS SCREENING: THE SAMPLE OF SİVAS

ABSTRACT&#x0D; Objective: The aim of the study is to screen for Type 2 Diabetes Mellitus (DM), to determine the risk of DM and to evaluate the factors affecting it.&#x0D; Method: It is a descriptive study. The population of the research consisted of people over the age of 18 living in Sivas who were not diagnosed with diabetes. The sample of the research consisted of individuals over the age of 18 who did not have diabetes and participated in the event, which was organized as part of the 14 November 2022 “World Diabetes Day” event, which continued between 08.00-17.00. In order to reach the universe, a stand was set up in the city center in the square where the people are concentrated. Capillary blood glucose measurement, a questionnaire including height, weight, demographic characteristics and Finnish Diabetes Risk Questionnaire (FINDRISK) were applied to the patients. FINDRISK consists of 8 questions. It determines an individual's risk of developing diabetes in the next ten years. Results are shown as frequencies, mean±standard deviation. Pearson correlation analysis, Student-T test and One way ANOVA test were applied. P

Susceptibility to car accidents due to sudden illness with truck drivers in northern Brazil

The prevalence of hypertension, diabetes, and obesity among truck drivers is closely related to the quality of life of this population and poses a significant vulnerability to the occurrence of car accidents. Objective: to identify the prevalence of these clinical conditions in drivers, as well as the correlation of their existence with emergency situations involving this population and the mechanisms of public health care. Methods: The QVS-80 questionnaire was applied to a sample population of 100 truck drivers in the municipality of Paraíso do Tocantins, located on the banks of the BR-153, to verify information related to quality of life and the presence or absence of Diabetes Mellitus, hypertension, and calculation of the Body Mass Index (BMI) to determine obesity according to the Brazilian Obesity Guidelines - ABESO (2016). In addition, blood pressure measurement and classification of individuals as hypertensive according to the VI Brazilian Guidelines for Arterial Hypertension of the Brazilian Society of Cardiology (2020), and as diabetics through random capillary blood glucose measurement in accordance with the guidelines of the Brazilian Society of Diabetes (2020) were performed. Results: The occurrence of car accidents involving trucks is directly related to the quality of life of their drivers, which was shown to be very poor due to the preexistence of chronic diseases such as obesity (41%), overweight (36%), diabetes (6%), and hypertension (60%). Conclusion: The work environment of truck drivers is ideal for sudden-onset events during driving and consequently the occurrence of accidents.

952-P: The Accuracy and Feasibility of Continuous Glucose Monitoring in COVID-19 Non-Critically Ill Hospitalized Patients—A Pilot Study

Background: Optimal glycemic control is associated with favorable outcomes in COVID-19 hospitalized patients. Frequent capillary blood glucose (CBG) monitoring is difficult to perform. Using continuous glucose monitoring (CGM) system to assist glycemic care can reduce the exposure of healthcare personnel and PPE usage. However, data on the accuracy of CGM in this setting are limited. Objective: To evaluate the accuracy and feasibility of real-time CGM (rt-CGM) in non-ICU hospitalized adult COVID-19 patients. Methods: This is a single-center prospective study of non-ICU hospitalized adult patients with COVID-19 infection who had hyperglycemia requiring insulin therapy during admission. Medtronic Guardian Connect rt-CGM sensor and transmitter were placed on the patient’s abdomen. Paired CBG and sensor glucose values were analyzed for accuracy of CGM using mean absolute relative difference (MARD) and Clarke Error Grid Analysis (CEGA). Results: Fifteen patients were enrolled. Mean age was 48.6 ± 17.9 years. Thirteen patients (86.7%) had pre-existing diabetes. Mean HbA1c was 10.6± 3.6%. Mean duration of CGM use was 6 ± 1.2 days and mean calibration was 2.6 ± 0.7 times/day. There were 253 paired CBG and CGM measurements. The overall MARD was 9.9 ± 9.3%. The lowest MARD was observed in the CBG range of 70-180 mg/dl (9.6 ± 9.0%). The percentages of glucose readings within ±15%/15 mg/dL, ±20%/20 mg/dL, and ±30%/30 mg/dL were 80.2%, 89.7%, and 95.3%, respectively. A total of 99.2% of the data points were in zone A and B of CEGA, and none were in zone E. Percent time in range on day 1 was 57.9 ± 22.9 and improved to 64.9 ± 18.1 in the last 72 hours of sensor wear. No adverse events from the CGM were observed. CGM reduced POC testing by 30%. Conclusions: Rt-CGM use in hospitalized patients with COVID-19 infection demonstrates high accuracy and potentially improves glucose control, reduces the frequency of CBG testing, and preserves medical resources. Disclosure C.Sakjirapapong: None. S.Sirinvaravong: None. L.Preechasuk: None. N.Thongtang: None. Funding Specific League Funds (R016421005)

Abstract #1401109: Quetiapine-induced Hypoglycemia in an Elderly Non-diabetic Patient with Dementia

Quetiapine is a second-generation antipsychotic agent (SGA) widely prescribed for the treatment of psychotic and mood disorders. In elderly patients, quetiapine is often used to treat psychotic symptoms associated with dementia. A metabolic syndrome phenotype of weight gain, hyperglycemia, and hyperlipidemia is a potential adverse effect of SGA’s, though hypoglycemia caused by SGA’s is documented. We report a case of quetiapine-induced hypoglycemia in a non-diabetic patient. A 79-year-old male with Lewy body dementia was admitted to hospital for management of a myocardial infarction. The patient had no history of diabetes mellitus, renal failure, or hepatic insufficiency, and nobody living with the patient was treated for diabetes. Plasma glucose on admission was 84 mg/dL. Quetiapine was started to control delirium, but within 24 h the patient had worsening confusion and a capillary blood glucose (CBG) measurement of 52 mg/dL. Symptoms improved with administration of dextrose, and the patient ultimately required a 10% dextrose infusion to maintain CBG’s >80 mg/dL. An ACTH-stimulation test (30 min stimulated cortisol 24.8 μg/dL, expected >18) and hypoglycemic medications panel (sulfonylureas and meglitinides) were unremarkable. Quetiapine was stopped, and hypoglycemia resolved. No hypoglycemia occurred during a subsequent 48-h diagnostic fast followed by a mixed meal tolerance test. Due to the patient’s advanced age and comorbidities, it was decided not re-challenge with quetiapine and observe for recurrence of hypoglycemia. Hypoglycemia is a rare complication of SGA’s, and diagnosis may be delayed or missed in patients with baseline confusion or agitation. In addition to quetiapine, there are case reports of hypoglycemia occurring during treatment with risperidone, olanzapine, aripiprazole, and paliperidone. Clozapine and olanzapine increase insulin release from isolated pancreatic islets in vitro, though quetiapine did not demonstrate this effect. However, endogenous hyperinsulinemia has been documented in case reports of quetiapine-induced hypoglycemia. The physiologic pathway by which SGA’s increase insulin release is unknown; some authors have focused on the antagonism of M1 muscarinic receptors, but the muscarinic M1 receptor antagonist pirenzepine has been demonstrated to reduce insulin secretion induced by the muscarinic receptor agonist carbachol from isolated rat pancreatic islets in vitro. Though the mechanism by which hypoglycemia occurs is unclear, this case demonstrates that hypoglycemia should be considered in patients with worsening mental status during treatment with SGA’s.

Pilot trial on the detection of patients with undiagnosed diabetes mellitus type 2 performed in community pharmacies in Valladolid. Environmental impact evaluation

The complications that DM2 can develop, and the undiagnosed population (6%) highlight the importance of screening at the population level. The aim of this work is to evaluate and verify whether the professional activity performed in pharmacies is a good point to detect patients with undiagnosed type 2 diabetes mellitus and to refer them for a possible diagnosis. Moreover, to evaluate the environmental impact of the actions. Findrisc questionnaire for patients who met the inclusion criteria and agreed to participate in the study. Basal capillary blood glucose measurement if the result was ≥15 points and referral to a physician if blood glucose was ≥110mg/dL. 44 pharmacies participated. The sample included 434 users; those with high or very high risk (Findrisc ≥15) underwent capillary basal glycemia, with a mean result of 124.51 mg/dL (SD=33.6). Out of the 89 patients referred to the physician (20.5%), the patients diagnosed with diabetes type 2 accounted for 3% of the analyzed sample. The number of newly diagnosed patients (3%) reflects that the community pharmacy is a good place for diabetes detection. In addition, the study reveals pharmacists' usefulness in their role as a health educator, since they provide guidance on healthy lifestyle habits to those patients not subject to physician referral. Furthermore, closer collaborations between physicians and pharmacists would be necessary in diabetes screening, since the return of information was low; although we can observe that in rural areas, where the relationship is close, the return rate was 85.2%.